Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) secondary analysis of a randomised, phase 3 trial /
Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT respon...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2018
|
| Sorozat: | LANCET ONCOLOGY
19 No. 11 |
| Tárgyszavak: | |
| doi: | 10.1016/S1470-2045(18)30618-1 |
| mtmt: | 30323811 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/23951 |